A non‐randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing‐remitting multiple sclerosis patients

Background Multiple sclerosis (MS) is a chronic disease characterized by demyelination, glial activation and axonal degeneration in the central nervous system. At the present, there is no certain remedy for this disease. However, available therapies often attenuate disease progress. Methods This study aims at identification of the effect of fingolimod on expanded disability status scale (EDSS) score and number of relapses in relapsing‐remitting...